Oral 4′-fluorouridine rescues nonhuman primates from advanced Lassa fever

Oral 4′-fluorouridine rescues nonhuman primates from advanced Lassa fever

There are no approved treatments for Lassa fever, which is estimated to cause 100,000 to 300,000 infections and 5,000 deaths annually in West Africa1,2. Recently, it was shown that 4′-fluorouridine (also known as EIDD-2749), an orally available ribonucleoside analogue, protected guinea pigs from lethal challenge with the lineage IV prototype Josiah strain of Lassa virus when treatment was delayed beyond the onset of clinical signs of disease3. H…